Schizophrenia. Schizophrenia
Conditions
Interventions
Intervention 1: Patients will receive memantine (once daily), in dosing titration as follows: week 1, 5mg/day
week 2, 10 mg/day
weeks 3-8, 20 mg/day, in addition to continuing tretment with antipsychotics for 8 weeks. Intervention 2: Patients will recieve placebo in control group.
Treatment - Drugs
Placebo
Patients will receive memantine (once daily), in dosing titration as follows: week 1, 5mg/day
weeks 3-8, 20 mg/day, in addition to continuing tretment with antipsychotics for 8 weeks.
Patients will recieve placebo in control group.
Sponsors
Faculty of pharmacy, Shahid Beheshti University of Medical Scienses
Eligibility
Sex/Gender
All
Age
16 Years to 65 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: patients aged 18-65 years old; patients that base on DSM V criteria has diagnosis of schizophrenia or schizoaffective disorder; patients who stable on medication four weeks prior to baseline and has not planned medication change. Exclusion criteria: subject that organic brain disease or neurological diagnosis (including neurological disorder or an active seizure); subjects who will meet the criteria for DSM-V diagnosis of alcohol or substance dependence within the last six month; any change of psychotropic medication within the previous four weeks.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PANSS score. Timepoint: At baseline, at the end of first and third month of the study. Method of measurement: Questionair.;Clinical evaluation. Timepoint: At baseline, at the end of first and third month of the study. Method of measurement: Questionair. | — |
Secondary
| Measure | Time frame |
|---|---|
| Assessment of inflammatory biomarkers (IL6, TNF, CRP). Timepoint: At baseline, at the end of first and third month of the study. Method of measurement: ELISA.;Assessment of inflammatory biomarkers (IL6, TNF, CRP). Timepoint: At baseline, at the end of first and third month of the study. Method of measurement: ELISA. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHamide Abbaspour
Faculty of pharmacy, Shahid Beheshti University of Medical Sciencses
Outcome results
None listed